American Society of Clinical OncologyManagement of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Clinical Practice Guideline

A systematic review identified 204 eligible publications from 2000 through 2017, with much of the evidence consisting of systematic reviews of observational data, consensus guidelines, case series, and case reports. Due to the paucity of high-quality evidence on management of immune-related adverse events, recommendations are based on expert consensus.

Hem/Onc Today (Healio)Results of KEYNOTE-716 Trial May ‘Level the Playing Field Against Melanoma’

The results, presented during the virtual ESMO Congress 2021, will substantially change the population of patients with melanoma who undergo treatment in the adjuvant setting, according to Jason J. Luke, MD: “Patients with stage IIB/C melanoma have similar rates of recurrence and melanoma specific survival to those with stage IIIA/B disease. Despite this, adjuvant anti-PD-1 […]

MedPage TodayAdjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma

Dr. Kenneth Grossmann commented after presenting the results at the ASCO Annual Meeting in June: “The overall survival impact of pembrolizumab was likely influenced by effective post-relapse treatment, with standard-of-care patients receiving PD-1 blockade.” Dr. Grossmann then concluded that “single-agent anti-PD-1 antibody treatment should be a standard-of-care option for adjuvant treatment of high-risk resected melanoma,” […]

Cancer Therapy AdvisorLEAP-004: Durable Responses in Advanced Melanoma Achieved With Lenvatinib Plus Pembrolizumab

Lead author of the study, Dr. Ana Maria Arance, who presented the results over the summer at the ASCO Annual Meeting, commented: “With additional follow-up, lenvatinib plus pembrolizumab continues to show clinically meaningful, durable responses in patients with advanced melanoma with confirmed progression on a PD-1 or PD-L1 inhibitor given alone or in combination. These […]